Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
The industry rank for Inhalation Sciences Sweden AB's Net-Net Working Capital or its related term are showing as below:
XSAT:ISAB's Price-to-Net-Net-Working-Capital is ranked better than 79.37% of 412
companies
in the Medical Devices & Instruments industry
Industry Median: 6.865
vs XSAT:ISAB: 2.75
Inhalation Sciences Sweden AB (XSAT:ISAB) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Inhalation Sciences Sweden AB Net-Net Working Capital Related Terms
Inhalation Sciences Sweden AB Net-Net Working Capital Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhalation Sciences Sweden AB Net-Net Working Capital Chart
XSAT:ISAB vs ABT, SYK, MDT: Net-Net Working Capital Comparison
For the Medical Devices subindustry, Inhalation Sciences Sweden AB's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhalation Sciences Sweden AB Price-to-Net-Net-Working-Capital vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inhalation Sciences Sweden AB's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Inhalation Sciences Sweden AB's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of kr0.05 mean?
Inhalation Sciences Sweden AB (XSAT:ISAB) has a Net-Net Working Capital of kr0.05 as of Jun. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Inhalation Sciences Sweden AB According to the industry distribution chart, Inhalation Sciences Sweden AB ranks #85 out of 412 companies in the Medical Devices & Instruments industry, placing it in the top 20.6%.
Is Inhalation Sciences Sweden AB's Net-Net Working Capital too high?
Inhalation Sciences Sweden AB's current Net-Net Working Capital is kr0.05. Based on the distribution chart, Inhalation Sciences Sweden AB ranks #85 out of 412 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Inhalation Sciences Sweden AB has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inhalation Sciences Sweden AB's Net-Net Working Capital compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Inhalation Sciences Sweden AB ranks #85 out of 412 companies for Net-Net Working Capital. This places Inhalation Sciences Sweden AB in the top 21% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 6.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Devices & Instruments company?
The median Net-Net Working Capital among Medical Devices & Instruments companies is 6.87, based on 412 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Inhalation Sciences Sweden AB For the Medical Devices & Instruments industry, the median Net-Net Working Capital is 6.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhalation Sciences Sweden AB's current Net-Net Working Capital is kr0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhalation Sciences Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Inhalation Sciences Sweden AB (XSAT:ISAB) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.43, compared to a current price of kr0.14 — trading 68% below its estimated fair value. The current Net-Net Working Capital is kr0.05. Inhalation Sciences Sweden AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Inhalation Sciences Sweden AB (XSAT:ISAB), the current Net-Net Working Capital is kr0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inhalation Sciences Sweden AB (XSAT:ISAB) Overvalued in 2026?
Based on GuruFocus' analysis, Inhalation Sciences Sweden AB stock appears to be undervalued.
The current stock price of kr0.14 is trading 68% below its estimated GF Value™ of kr0.43.
GuruFocus considers Inhalation Sciences Sweden AB to be Possible Value Trap.
Key valuation signals for XSAT:ISAB:
Net-Net Working Capital: kr0.05
GF Value™: kr0.43 vs. price of kr0.14 (68% below fair value)
No single metric tells the full story. See the XSAT:ISAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inhalation Sciences Sweden AB develops and commercializes patented lab instrument for inhalation research. Its products include PreciseInhale an advanced laboratory system used to measure inhaled particles and their effect on lungs, and LaminarPace tool for drying small amounts of the drug substance.
25GF Score
Get the complete analysis for XSAT:ISAB
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ISAB has been successfully added to your 
